Breakthrough: Takeda’s QDENGA Approved in India Despite Prior Dengue
Takeda Biopharmaceuticals India announced on July 20, 2026 that India’s drug regulatory authority has granted market authorisation for QDENGA, its dengue vaccine, for people aged 4–60 years. The company said QDENGA is the first dengue vaccine approved in India that can be given regardless of prior dengue exposure, removing the need for pre-vaccination testing.
Dengue is a mosquito-borne viral disease that affects more than 125 countries and is a major public health threat. Takeda noted that India accounts for nearly one-third of the global dengue burden; reported cases in 2025 exceeded 113,000, though modelling suggests the true burden in India may be far higher, likely amounting to tens of millions of infections each year.
QDENGA is a tetravalent, live-attenuated vaccine formulated to protect against all four dengue virus serotypes. It is administered subcutaneously as a 0.5 mL dose in a two-dose schedule, with the second dose given three months after the first. The World Health Organization has recommended the vaccine for use in dengue-endemic settings and granted WHO prequalification to QDENGA a few years earlier.
Takeda said the Indian approval rests on data from its global clinical development programme, which included 19 Phase 1, 2 and 3 trials with more than 28,000 participants in both endemic and non-endemic regions. The pivotal Phase III TIDES (DEN-301) trial enrolled over 20,000 participants across eight countries and evaluated long-term safety and efficacy.
The approval is also supported by a Phase III trial conducted in India (DEN-302) that assessed safety and immunogenicity in 4–60 year-olds. The company said, “The study demonstrated that QDENGA was found to be tolerated, safe and immunogenic in healthy adults, adolescents and children. These clinical outcomes are further supported by real-world evidence generation and ongoing pharmacovigilance to deepen understanding of the vaccine’s safety and impact.”
Mahender Nayak, Takeda’s Head of Intercontinental Markets, said the latest seven-year data show continued protection against dengue infection and hospitalisation across all four serotypes, calling the result “an important milestone for communities and health systems.” He noted that since its 2022 launch QDENGA has been approved in 43 countries and more than 32 million doses have been distributed globally.
Peter Streibl, General Manager for the Southeast Asia and India Cluster, said dengue is a shared regional challenge that requires cross-border collaboration and pledged Takeda’s support for access to QDENGA where approved, alongside efforts to strengthen surveillance, awareness, vector control and community engagement. Goh Choo Beng, Medical Affairs Head for the cluster, added that all four dengue serotypes circulate in parts of India and that QDENGA is designed to protect regardless of prior exposure.
Original Source: https://www.thehindubusinessline.com/news/national/takedas-qdenga-approved-in-india-can-be-given-despite-pre-exposure-to-dengue/article71244817.ece
Category:
Tags:
Publish Date: 2026-07-20 16:41:00